Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
CDKN2A (INK4a/ARF) is frequently disrupted in various types of human cancer, and germline mutations of this locus can confer susceptibility to melanoma and other tumours. However, because CDKN2A encodes two distinct cell cycle inhibitory proteins, p16INK4a and p14ARF (p19Arf in mice), the mechanism of tumour suppression by CDKN2A has remained controversial. Genetic disruption of Cdkn2a(p19Arf) (hereafter Arf) alone predisposes mice to tumorigenesis, demonstrating that Arf is a tumour-suppressor gene in mice. We mutated mice specifically in Cdkn2a(p16Ink4a) (hereafter Ink4a). Here we demonstrate that these mice, designated Ink4a*/*, do not show a significant predisposition to spontaneous tumour formation within 17 months. Embryo fibroblasts derived from them proliferate normally, are mortal, and are not transformed by oncogenic HRAS. The very mild phenotype of the Ink4a*/* mice implies that the very strong phenotypes of the original Ink4a/ArfDelta2,3 mice were primarily or solely due to loss of Arf. However, Ink4a*/Delta2,3 mice that are deficient for Ink4a and heterozygous for Arf spontaneously develop a wide spectrum of tumours, including melanoma. Treatment of these mice with the carcinogen 7,12-dimethylbenzanthracene (DMBA) results in an increased incidence of melanoma, with frequent metastases. Our results show that, in the mouse, Ink4a is a tumour-suppressor gene that, when lost, can recapitulate the tumour predisposition seen in humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“Mutations in p16 , Rb , ARF and TP53 are frequently found in human cancers, and their tumour-suppressive roles have been confirmed in vivo using genetically modified mouse models [25 -29].”
From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [28]
In the citing paper
“For example, mouse embryonic fibroblasts (MEFs) lacking p53 [72] but not Ink4a (p16) or RB [73,74,75] escape Ras-induced senescence.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [74]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“MEFs mutated in components of the Rb1 or Trp53 pathways are defective in various aspects of proliferative control, displaying altered proliferation rates, cell-cycle distributions and cell size compared with wild-type cell”
BackgroundTodaro, G. J., & Green, H. (1963) · The Journal of Cell Biology · doi:10.1083/jcb.17.2.299 · Cited by 2,736
Morgenstern, J. P., & Land, H. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.12.3587 · Cited by 2,101
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585 · cited 1×
“No melanomas were observed in DMBA-treated control animals, either in those followed by us for 8 months or in historical control”
BackgroundTumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Schwenk, F., Baron, U., & Rajewsky, K. (1995) · Nucleic Acids Research · doi:10.1093/nar/23.24.5080 · Cited by 1,289
Kiyono, T., Foster, S. A., Koop, J. I., McDougall, J. K., Galloway, D. A., & Klingelhutz, A. J. (1998) · Nature · doi:10.1038/23962 · Cited by 1,206 · cited 1×
“p16 INK4a and its downstream targets, the RB1 family members, have been implicated in this response in both huma”
BackgroundBmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF
Jacobs, J. J. L., Scheijen, B., Voncken, J.-W., Kieboom, K., Berns, A., & van Lohuizen, M. (1999) · Genes & Development · doi:10.1101/gad.13.20.2678 · Cited by 1,065
Self-citationThe p16INK4a/CDKN2A tumor suppressor and its relatives
Ruas, M., & Peters, G. (1998) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(98)00017-1 · Cited by 911
Cited by
Items 101–200 of 567
Oruetxebarria, I., Venturini, F., Kekarainen, T., Houweling, A., Zuijderduijn, L. M. P., Mohd-Sarip, A., Vries, R. G. J., Hoeben, R. C., & Verrijzer, C. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309333200 · Cited by 160
Gizard, F., Amant, C., Barbier, O., Bellosta, S., Robillard, R., Percevault, F., Sevestre, H., Krimpenfort, P., Corsini, A., Rochette, J., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci22756 · Cited by 160
“Finally, the in vivo role of p16 in mediating the growth-inhibitory effects of PPARα activation were further analyzed using p16–/– mice (29).”
BackgroundMethodSelf-citationBiochemical and cellular mechanisms of mammalian CDK inhibitors: a few unresolved issues
Pei, X.-H., & Xiong, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1208611 · Cited by 158
“…mice developed a relatively mild phenotype of testicular hypertrophy (Zindy et al., 2000), p16 null mice developed sarcoma, lymphoma and melanomas (Krimpenfort et al., 2001; Sharpless et al., 2001), and p18 null mice developed widespread hyperplasia, organomegaly, and pituitary tumor (Franklin et…”
BackgroundThe Senescence Markers p16INK4A, p14ARF/p19ARF, and p21 in Organ Development and Homeostasis
Wagner, K.-D., & Wagner, N. (2022) · Cells · doi:10.3390/cells11121966 · Cited by 156
“Specific p16INK4A knockout mice which retained p14ARF/p19ARF function displayed an increased incidence of spontaneous and carcinogen-induced cancers [132] and melanomas [145] and thymus hyperplasia [132].”
BackgroundCell cycle in mouse development
Ciemerych, M. A., & Siciński, P. (2005) · Oncogene · doi:10.1038/sj.onc.1208608 · Cited by 172
“Subsequently, mice lacking only p16INK4a (but expressing intact p19ARF) were generated (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundThe role of cellular senescence and SASP in tumour microenvironment
Takasugi, M., Yoshida, Y., Hara, E., & Ohtani, N. (2023) · The FEBS Journal · doi:10.1111/febs.16381 · Cited by 144
Arf tumor suppressor promoter monitors latent oncogenic signals in vivo
Zindy, F., Williams, R. T., Baudino, T. A., Rehg, J. E., Skapek, S. X., Cleveland, J. L., Roussel, M. F., & Sherr, C. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536808100 · Cited by 149
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 173
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Sekulic, A., Haluska, P., Miller, A. J., De Lamo, J. G., Ejadi, S., Pulido, J. S., Salomao, D. R., Thorland, E. C., Vile, R. G., Swanson, D. L., et al. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.7.825 · Cited by 148
Noscapine alters microtubule dynamics in living cells and inhibits the progression of melanoma
Landen, J. W., Lang, R., McMahon, S. J., Rusan, N. M., Yvon, A.-M. C., Adams, A. W., Sorcinelli, M. D., Campbell, R., Bonaccorsi, P., Ansel, J. C., et al. (2002) · PubMed · doi:10.7275/3634 · Cited by 144
Ink4a/Arf links senescence and aging
Sharpless, N. E. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.06.025 · Cited by 142
Molecular mechanisms of photocarcinogenesis
Matsumura, Y. (2002) · Frontiers in Bioscience · doi:10.2741/matsumur · Cited by 143
ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence
Ha, L., Ichikawa, T., Anver, M., Dickins, R., Lowe, S., Sharpless, N. E., Krimpenfort, P., DePinho, R. A., Bennett, D. C., Sviderskaya, E. V., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611638104 · Cited by 143
Self-citationZou, X., Ray, D., Aziyu, A., Christov, K., Boiko, A. D., Gudkov, A. V., & Kiyokawa, H. (2002) · Genes & Development · doi:10.1101/gad.1033002 · Cited by 142
“Mice lacking p16Ink4a with intact p19Arf are susceptible to tumorigenesis to a lesser extent (Krimpenfort et al. 2001; Sharpless et al. 2001).”
BackgroundInfluentialMunro, J., Barr, N. I., Ireland, H., Morrison, V., & Parkinson, E. K. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.01.017 · Cited by 141
Shvarts, A., Brummelkamp, T. R., Scheeren, F., Koh, E., Daley, G. Q., Spits, H., & Bernards, R. (2002) · Genes & Development · doi:10.1101/gad.929302 · Cited by 140
Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation
Zeng, H., Jorapur, A., Shain, A. H., Lang, U. E., Torres, R., Zhang, Y., McNeal, A. S., Botton, T., Lin, J., Donne, M., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.014 · Cited by 137
Takeuchi, S., Takahashi, A., Motoi, N., Yoshimoto, S., Tajima, T., Yamakoshi, K., Hirao, A., Yanagi, S., Fukami, K., Ishikawa, Y., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0801 · Cited by 136
Abdel-Malek, Z. A., Kadekaro, A. L., & Swope, V. B. (2010) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2010.00679.x · Cited by 134
“Further evidence for this observation was provided by transgenic mouse models in which these mutations that lead to aberrant DNA damage response resulted in melanoma formation (Krimpenfort et al., 2001; Sharpless and Chin, 2003).”
BackgroundA Conditional Mouse Model for Malignant Mesothelioma
Jongsma, J., van Montfort, E. H. N., Vooijs, M., Zevenhoven, J., Krimpenfort, P., van der Valk, M., van de Vijver, M. J., & Berns, A. J. M. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.030 · Cited by 138
Self-citationKumar, S., Park, S. H., Cieply, B., Schupp, J., Killiam, E., Zhang, F., Rimm, D. L., & Frisch, S. M. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-10 · Cited by 134
“In this connection, a loss of heterozygosity of the CDKN2a locus promotes tumor progression significantly in both mouse and human contexts, revealing a haploinsufficiency effect and validating the importance of the 2-fold regulation of p14ARF expression observed here (24, 40, 52, 62).”
BackgroundBrenner, E., Schörg, B. F., Ahmetlić, F., Wieder, T., Hilke, F. J., Simon, N., Schroeder, C., Demidov, G. M., Riedel, T., Fehrenbacher, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14987-6 · Cited by 147
Germline mutation of ARF in a melanoma kindred
Hewitt, C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.11.1273 · Cited by 132
PARDAL, R., MOLOFSKY, A. V., HE, S., & MORRISON, S. J. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.057 · Cited by 131
“Ink4a deletion in mice and humans is associated with lymphoma, lung adenoma, brain tumors, melanoma, and other cancers (Krimpenfort et al. 2001; Sharpless et al. 2001; Sherr and McCormick 2002).”
BackgroundMitochondrial p32 Is a Critical Mediator of ARF-Induced Apoptosis
Itahana, K., & Zhang, Y. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.002 · Cited by 145
Immortalisation and transformation revisited
Drayton, S., & Peters, G. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00271-4 · Cited by 148
FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf
Bouchard, C., Lee, S., Paulus-Hock, V., Loddenkemper, C., Eilers, M., & Schmitt, C. A. (2007) · Genes & Development · doi:10.1101/gad.453107 · Cited by 126
“These data and the previous observation that deletion of Arf, but not of Ink4a, at this locus cooperates with Myc in lymphoma development via interrupting oncogenic signaling to p53 (Eischen et al. 1999; Krimpenfort et al. 2001) strongly suggest that dnFoxO facilitates Myc-induced lymphomagenesis through reduction of…”
BackgroundSviderskaya, E. V., Gray-Schopfer, V. C., Hill, S. P., Smit, N. P., Evans-Whipp, T. J., Bond, J., Hill, L., Bataille, V., Peters, G., Kipling, D., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.10.723 · Cited by 123
Health effects from stratospheric ozone depletion and interactions with climate change
de Gruijl, F. R., Longstreth, J. D., Norval, M., Cullen, A. P., Slaper, H., Kripke, M. L., Takizawa, Y., & van der Leun, J. C. (2003) · Photochemical & Photobiological Sciences · doi:10.1039/b211156j · Cited by 141
Genetic alterations in pancreatic carcinoma.
Schneider, G., & Schmid, R. M. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-15 · Cited by 156
Rowland, B. D., Denissov, S. G., Douma, S., Stunnenberg, H. G., Bernards, R., & Peeper, D. S. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00085-5 · Cited by 120
“Recent data, however, revealPrevious studies (Bates et al., 1998; Dimri et al., 2000) showed that wild-type E2F-1 induced the human p14ARF gene, that p16INK4a is dispensable both for spontaneous and RASV12- induced senescence in MEFs (Krimpenfort et al., 2001;whereas E2F-DB did not.”
BackgroundKrones-Herzig, A., Adamson, E., & Mercola, D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2628034100 · Cited by 118
Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model
Kannan, K., Sharpless, N. E., Xu, J., O'Hagan, R. C., Bosenberg, M., & Chin, L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0336397100 · Cited by 116
Cellular senescence: Its role in tumor suppression and aging
Ohtani, N., Mann, D. J., & Hara, E. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01123.x · Cited by 114
Senescent Cells: A Therapeutic Target in Cardiovascular Diseases
Suda, M., Paul, K. H., Minamino, T., Miller, J. D., Lerman, A., Ellison-Hughes, G. M., Tchkonia, T., & Kirkland, J. L. (2023) · Cells · doi:10.3390/cells12091296 · Cited by 112
Involvement of the INK4a/Arf gene locus in senescence
Collins, C. J., & Sedivy, J. M. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00048.x · Cited by 113
Hyperproliferation, induction of c-Myc and 14-3-3σ, but no cell fragility in keratin-10-null mice
Reichelt, J., & Magin, T. M. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.13.2639 · Cited by 124
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
Freedberg, D. E., Rigas, S. H., Russak, J., Gai, W., Kaplow, M., Osman, I., Turner, F., Randerson-Moor, J. A., Houghton, A., Busam, K., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn157 · Cited by 109
“Furthermore, mice hemizygous for p19Arf and lacking p16Ink4a were more likely to develop tumors (including melanomas) and to develop them more rapidly than those that only lacked p16Ink4a (49, 50).”
BackgroundHaplo-insufficiency? Let me count the ways: Figure 1.Preprint
Quon, K. C., & Berns, A. J. M. (2001) · Genes & Development · doi:10.1101/gad.949001 · Cited by 109
“Moreover, in the absence of a functional p16Ink4a tumor suppressor gene, loss of a single Arf allele appears to be sufficient for tumorigenesis (Krimpenfort et al. 2001).”
BackgroundSelf-citationManganese Superoxide Dismutase Induces p53-Dependent Senescence in Colorectal Cancer Cells
Behrend, L., Mohr, A., Dick, T., & Zwacka, R. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7758-7769.2005 · Cited by 109
Adenovirus-mediated overexpression of p14ARF induces p53 and Bax-independent apoptosis
Hemmati, P., Gillissen, B. F., von Haefen, C., Wendt, J., Stärck, L., Güner, D., Dörken, B., & Daniel, P. T. (2002) · Oncogene · doi:10.1038/sj.onc.1205458 · Cited by 124
“The generation of knock-out mice for p16INK4a or p14ARF has clearly demonstrated that both genes are involved in tumor suppression (Kamijo et al., 1999; Krimpenfort et al., 2001).”
BackgroundHuot, T. J., Rowe, J., Harland, M., Drayton, S., Brookes, S., Gooptu, C., Purkis, P., Fried, M., Bataille, V., Hara, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.23.8135-8143.2002 · Cited by 107
Current State of Animal (Mouse) Modeling in Melanoma Research
Kuzu, O. F., Nguyen, F. D., Noory, M. A., & Sharma, A. K. (2015) · Cancer Growth and Metastasis · doi:10.4137/cgm.s21214 · Cited by 138
Consistent expression of the stem cell renewal factor BMI‐1 in primary and metastatic melanoma
Mihic‐Probst, D., Kuster, A., Kilgus, S., Bode‐Lesniewska, B., Ingold‐Heppner, B., Leung, C., Storz, M., Seifert, B., Marino, S., Schraml, P., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22891 · Cited by 107
“p16 knock out mice develop normally, but have increased cancer susceptibility and develop multiple malignancies.(8,9) p14 promotes cell cycle arrest and apoptosis via its regulation of p53 stability stages.”
BackgroundInoue, K., Zindy, F., Randle, D. H., Rehg, J. E., & Sherr, C. J. (2001) · Genes & Development · doi:10.1101/gad.929901 · Cited by 118
“These patterns of protein expression are typical of mutant forms of p53, which neither transcriptionally activate Mdm2 to trigger p53 destruction (Haupt et al. 1997; Kubbutat et al. 1997) nor repress Arf transcription (Kamijo et al. 1998; Stott et al. 1998).”
BackgroundStraume, O., Smeds, J., Kumar, R., Hemminki, K., & Akslen, L. A. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64174-0 · Cited by 124
“Recent publications have also demonstrated that p16 knockout mice, as well as mice with p16-specific mutations or deletions, show an increased incidence of spontaneous and carcinogen-induced cancers including melanoma.(35,36) We previously showed that loss of p16 protein expression was associated with increased tumor…”
BackgroundCell Type-Specific Tumor Suppression by Ink4a and Arf in Kras-Induced Mouse Gliomagenesis
Uhrbom, L., Kastemar, M., Johansson, F. K., Westermark, B., & Holland, E. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3588 · Cited by 104
Epstein-Barr virus LMP1 blocks p16INK4a–RB pathway by promoting nuclear export of E2F4/5
Ohtani, N., Brennan, P., Gaubatz, S., Sanij, E., Hertzog, P., Wolvetang, E., Ghysdael, J., Rowe, M., & Hara, E. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302085 · Cited by 104
Myc-Mediated Proliferation and Lymphomagenesis, but Not Apoptosis, Are Compromised by E2f1 Loss
Baudino, T. A., Maclean, K. H., Brennan, J. A., Parganas, E., Yang, C., Aslanian, A., Lees, J. A., Sherr, C. J., Roussel, M. F., & Cleveland, J. L. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00102-3 · Cited by 111
Petrenko, O., Zaika, A. I., & Moll, U. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5540-5555.2003 · Cited by 123
p53-Dependent and -Independent Functions of the Arf Tumor Suppressor
SHERR, C. J., BERTWISTLE, D., DEN BESTEN, W., KUO, M.-L., SUGIMOTO, M., TAGO, K., WILLIAMS, R. T., ZINDY, F., & ROUSSEL, M. F. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.004 · Cited by 101
Tian, X., Azpurua, J., Ke, Z., Augereau, A., Zhang, Z. D., Vijg, J., Gladyshev, V. N., Gorbunova, V., & Seluanov, A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418203112 · Cited by 101
Berggren, P., Kumar, R., Sakano, S., Hemminki, L., Wada, T., Steineck, G., Adolfsson, J., Larsson, P., Norming, U., Wijkström, H., et al. (2003) · PubMed · Cited by 114
Haploinsufficiency of p18INK4c Sensitizes Mice to Carcinogen-Induced Tumorigenesis
Bai, F., Pei, X.-H., Godfrey, V. L., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.4.1269-1277.2003 · Cited by 100
“tumors—mostly sarcomas and lymphomas late in life (16, 28).”
BackgroundInk4‐Arf locus in cancer and aging
Sherr, C. J. (2012) · WIREs Developmental Biology · doi:10.1002/wdev.40 · Cited by 98
Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo
Sharpless, N. E., Kannan, K., Xu, J., Bosenberg, M., & Chin, L. (2003) · Oncogene · doi:10.1038/sj.onc.1206809 · Cited by 116
“This work builds upon previous results in the mouse (Bardeesy et al., 2001; Krimpenfort et al., 2001; Sotillo et al., 2001; Sharpless et al., 2002) to provide genetic evidence of a critical role of both products of the Ink4a/ Arf locus in the biology of melanoma.”
ResultWatanabe, M., Moon, K. D., Vacchio, M. S., Hathcock, K. S., & Hodes, R. J. (2014) · Immunity · doi:10.1016/j.immuni.2014.04.006 · Cited by 97
“Indeed, none of the gene-ablated strains that we have tested here, when characterized by others, recapitulate the phenotype of Trp53 / mice for susceptibility to spontaneous tumor development (Deng et al., 1995; Fero et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001).”
Molecular Regulation of Melanocyte Senescence
Bennett, D. C., & Medrano, E. E. (2002) · Pigment Cell Research · doi:10.1034/j.1600-0749.2002.02036.x · Cited by 95
Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease
Dai, L., Qureshi, A. R., Witasp, A., Lindholm, B., & Stenvinkel, P. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.06.015 · Cited by 94
“On the one hand, the inhibition of p16, pRB, p53 or p21 tumor suppressor pathways could diminish the defensive effect of senescent cells against cancer and increase the risk of cancer development [116].”
BackgroundDrayton, S., Rowe, J., Jones, R., Vatcheva, R., Heavens, D., Marshall, J. F., Fried, M., & Peters, G. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00242-3 · Cited by 98
A Melanoma Molecular Disease Model
Vidwans, S. J., Flaherty, K. T., Fisher, D. E., Tenenbaum, J. M., Travers, M., & Shrager, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018257 · Cited by 106
“. Mouse studies indicate that either is sufficient for melanoma predisposition and that they might, in fact, cooperate to drive disease progression”
BackgroundTaniai, M., Higuchi, H., Burgart, L. J., & Gores, G. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36021 · Cited by 99
Does vitamin D protect against DNA damage?
Nair-Shalliker, V., Armstrong, B. K., & Fenech, M. (2012) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2012.02.005 · Cited by 92
Senescence of renal cells: molecular basis and clinical implications
Melk, A. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg322 · Cited by 91
“P16 and p19 have overlapping and complementary roles in mouse embryonic fibroblasts growth arrest in vitro [30] with the notion that p19 is more potent [31].”
Ink4a/arf deficiency promotes ultraviolet radiation-induced melanomagenesis.
Recio, J. A., Noonan, F. P., Takayama, H., Anver, M. R., Duray, P. H., Rush, W. L., Lindner, G., Fabo, E. C. D., DePinho, R. A., & Merlino, G. T. (2002) · PubMed · Cited by 117
Targeting hypoxia tolerance in cancer
Wouters, B. G., van den Beucken, T., Magagnin, M. G., Lambin, P., & Koumenis, C. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2003.12.004 · Cited by 96
Mouse models for melanoma: a personal perspective
Becker, J. C., Houben, R., Schrama, D., Voigt, H., Ugurel, S., & Reisfeld, R. A. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.00986.x · Cited by 106
Bertin, R., Acquaviva, C., Mirebeau‐Prunier, D., Guidal, C., VILMER, E., & Cavé, H. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10188 · Cited by 97
“Both proteins have been proved to be associated with oncogenesis when selectively inactivated (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundRapid target gene validation in complex cancer mouse models using re‐derived embryonic stem cells
Huijbers, I. J., Ali, R. B., Pritchard, C. E. J., Cozijnsen, M., Kwon, M., Proost, N., Song, J., de Vries, H., Badhai, J., Sutherland, K., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201303297 · Cited by 94
“ESCs were also derived from Nf2 F/F ; Trp53 F/F ;Cdkn2a */* mice, which carry — in addition to conditional Nf2 and Trp53 alleles — a homozygous mutation in Cdkn2a that results in loss of p16 Ink4a expression but retention of the alternative reading frame protein p19 Arf (Krimpenfort et al , 2001).”
Self-citationSuppression of p16 alleviates the senescence-associated secretory phenotype
(2021) · doi:10.18632/aging.202640 · Cited by 84
“expression? p16 is a critical cell cycle regulator, and its suppression both enhances proliferation and allows for senescence bypass [8-10, 12, 70, 71].”
BackgroundChen, Z., Guo, Y., Zhao, D., Zou, Q., Yu, F., Zhang, L., & Xu, L. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.808208 · Cited by 87
“The p16INK4A protein is a CDK (cyclindependent kinase) inhibitor, and it functions as a predominant suppressor of melanoma (Krimpenfort et al., 2001; Sviderskaya et al., 2002; Goldstein et al., 2006; Bennett, 2015).”
BackgroundNoonan, F. P., Dudek, J., Merlino, G., & De Fabo, E. C. (2003) · Pigment Cell Research · doi:10.1034/j.1600-0749.2003.00014.x · Cited by 87
Cutaneous melanoma in genetically modified animals
Larue, L., & Beermann, F. (2007) · Pigment Cell Research · doi:10.1111/j.1600-0749.2007.00411.x · Cited by 107
Zhang, S., Qian, X., Redman, C., Bliskovski, V., Ramsay, E. S., Lowy, D. R., & Mock, B. A. (2003) · Oncogene · doi:10.1038/sj.onc.1206257 · Cited by 92
“Selective targeting of p16 in mice place them at an increased risk for tumor development (Krimpenfort et al., 2001; Sharpless et al., 2001).”
BackgroundPrevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors
Domínguez, G., Silva, J., Garcia, J. M., Silva, J. M., Rodríguez, R., Muñoz, C., Chacón, I., Sanchez, R., Carballido, J., Colás, A., et al. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00133-7 · Cited by 98
Kranc, K. R., Bamforth, S. D., Bragança, J., Norbury, C., van Lohuizen, M., & Bhattacharya, S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7658-7666.2003 · Cited by 86
Genetic and Epigenetic Changes in Mammary Epithelial Cells May Mimic Early Events in Carcinogenesis
Tlsty, T. D., Crawford, Y., Holst, C. R., Fordyce, C., Zhang, J., McDermott, K. M., Kozakiewicz, K., & Gauthier, M. L. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000048773.95897.5f · Cited by 89
“The dissection of the contribution of these two loci in the initiation and progression of different cancers has demonstrated that loss of p16INK4a alone (with retention of p19Arf) leads to tumor predisposition in mice (23).”
Role of the RB Tumor Suppressor in Cancer
Yamasaki, L. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_9 · Cited by 84
The p16INK4a tumor suppressor controls p21WAF1 induction in response to ultraviolet light
Almohanna, M., Al‐Khalaf, H. H., Al‐Yousef, N., & Aboussekhra, A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl1075 · Cited by 92
“Furthermore, mice lacking p16 are tumor prone and develop different types of cancer, particularly after exposure to carcinogens (30,31).”
BackgroundDistinct E2F‐mediated transcriptional program regulates p14 ARF gene expression
Komori, H., Enomoto, M., Nakamura, M., Iwanaga, R., & Ohtani, K. (2005) · The EMBO Journal · doi:10.1038/sj.emboj.7600836 · Cited by 97
Choi, B. Y., Choi, H. S., Ko, K., Cho, Y., Zhu, F., Kang, B. S., Ermakova, S. P., Ma, W., Bode, A. M., & Dong, Z. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb960 · Cited by 95
“The specific region of interaction between JNK1 or JNK3 and GST-p16INK4a was confirmed by the use of an N-terminally truncated (residues 20–60) GST-p16INK4a fusion protein (GST-p16DN40; Fig.”
BackgroundInfluentialVidal, A., Millard, S. S., Miller, J. P., & Koff, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m112090200 · Cited by 83
Grillo, M., Bott, M. J., Khandke, N., McGinnis, J. P., Miranda, M., Meyyappan, M., Rosfjord, E. C., & Rabindran, S. K. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9066-y · Cited by 89
Tanaka, T. U., Akatsuka, S., Ozeki, M., Shirase, T., Hiai, H., & Toyokuni, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207555 · Cited by 85
“However, since no occurrence of RCC has been observed in p16 knockout mice studies (Serrano et al., 1996; Krimpenfort et al., 2001; Sharpless et al., 2001), other alterations might also play a role in oxidative stress-induced carcinogenesis.”
BackgroundHafkamp, H. C., Mooren, J. J., Claessen, S. M. H., Klingenberg, B., Voogd, A. C., Bot, F., Klußmann, J. P., Hopman, A. H. N., Manni, J. J., Kremer, B., et al. (2009) · Modern Pathology · doi:10.1038/modpathol.2009.23 · Cited by 81
Myc and E2F1 induce p53 through p14ARF-independent mechanisms in human fibroblasts
Lindström, M. S., & Wiman, K. G. (2003) · Oncogene · doi:10.1038/sj.onc.1206659 · Cited by 94
“Studies in mice indicate that both p16INK4a and p19ARF are bona fide tumor suppressors (Kamijo et al., 1997; Krimpenfort et al., 2001; Sharpless et al., 2001). p16INK4a induces growth arrest and senescence in human and mouse cells (for a review see, Drayton and Peters, 2002). p19ARF inhibits cell…”
BackgroundMühleder, S., Fernández-Chacón, M., García-Gónzalez, I., & Benedito, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03664-y · Cited by 89
Targeting Cell Senescence and Senolytics: Novel Interventions for Age-Related Endocrine Dysfunction
Suda, M., Paul, K. H., Tripathi, U., Minamino, T., Tchkonia, T., & Kirkland, J. L. (2024) · Endocrine Reviews · doi:10.1210/endrev/bnae010 · Cited by 99
Building ‘validated’ mouse models of human cancer
Hann, B. C., & Balmain, A. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00283-0 · Cited by 91
Cellular senescence and kidney aging
Rex, N., Melk, A., & Schmitt, R. (2023) · Clinical Science · doi:10.1042/cs20230140 · Cited by 101
Molecular defects in the pathogenesis of pituitary tumours
Levy, A., & Lightman, S. L. (2003) · Frontiers in Neuroendocrinology · doi:10.1016/s0091-3022(03)00012-8 · Cited by 86
Ras-Induced Senescence and its Physiological Relevance in Cancer
DiMauro, T., & David, G. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357998 · Cited by 76
“Consistent with the notion that p19ARF, by contrast to p16INK4a, mediates Ras-induced senescence in mouse cells, murine fibroblasts derived from p19ARF null animals failed to arrest upon forced expression of activated K-Ras, while p16INK4a null primary mouse fibroblasts remain susceptible to oncogene-induced senescenc…”
BackgroundMilyavsky, M., Shats, I., Cholostoy, A., Brosh, R., Buganim, Y., Weisz, L., Kogan, I., Cohen, M., Shatz, M., Madar, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.022 · Cited by 79
What have animal models taught us about the p53 pathway?
Lozano, G., & Zambetti, G. P. (2005) · The Journal of Pathology · doi:10.1002/path.1704 · Cited by 76
“The resulting p16 Ink4a -deficient mice were only mildly tumour-prone by 17 months of age [73].”
BackgroundTsai, K. Y., & Tsao, H. (2004) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.30037 · Cited by 87
“Interestingly, the mouse homolog p19ARF appears to be haploinsufficient for mel- anoma suppression on a p16Ink4a-null background implying that partial loss of function of ARF may be sufficient to predispose to melanoma in certain genetic backgrounds [Krimpenfort et al., 2001].”
BackgroundPancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets
Maharjan, C. K., Ear, P. H., Tran, C. G., Howe, J. R., Chandrasekharan, C., & Quelle, D. E. (2021) · Cancers · doi:10.3390/cancers13205117 · Cited by 76
Biology of MET: a double life between normal tissue repair and tumor progression.
Petrini, I. (2015) · PubMed Central · doi:10.3978/j.issn.2305-5839.2015.03.58 · Cited by 75
“The gain of function mutation of the cell cycle control cyclin (CDK4) and the deletion of its inhibitor CDKN2A (p19INK) are key genetic events frequently observed in melanomas (128,129).”
BackgroundWilliams, T. M., Lee, H., Cheung, M. W.-C., Cohen, A. W., Razani, B., Iyengar, P., Scherer, P. E., Pestell, R. G., & Lisanti, M. P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402064200 · Cited by 88
Wikman, H., & Kettunen, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.4.515 · Cited by 72
p53 Protein and Pathogenesis of Melanoma and Nonmelanoma Skin Cancer
Benjamin, C. L., Melnikova, V. O., & Ananthaswamy, H. N. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-77574-6_21 · Cited by 84
Metadata
- Authors
- Krimpenfort, P., Quon, K. C., Mooi, W. J., Loonstra, A., & Berns, A.
- Affiliations
- The Netherlands Cancer Institute (NL)
- Corresponding author
- Berns, Anton
- Venue
- Nature
- Published
- 2001-09
- Volume
- 413
- Issue
- 6851
- Pages
- 83-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2003223749
- Cited by
- 568
- References
- 27
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 27 · 2023: 9 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 7 · 2015: 13 · 2014: 20 · 2013: 22 · 2012: 12
- FWCI
- 25.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- p16INK4a, CDKN2A, p14ARF, metastatic melanoma, cancer susceptibility, tumor suppressor, germline mutations, melanoma predisposition, DMBA-induced carcinogenesis, embryonic fibroblasts, mouse model
- MeSH terms
- Animals, Carcinogens, Cell Transformation, Neoplastic, Cells, Cultured, Embryo, Mammalian, Female, Fibroblasts, Humans, Male, Melanoma, Experimental, Proteins, Genes, ras, 9,10-Dimethyl-1,2-benzanthracene, Gene Deletion, Point Mutation, Cyclin-Dependent Kinase Inhibitor p16, Genes, p16, Genetic Predisposition to Disease, Tumor Suppressor Protein p14ARF, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.